Compare SKIL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKIL | MDXH |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Belgium |
| Employees | 2247 | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 41.1M |
| IPO Year | N/A | 2021 |
| Metric | SKIL | MDXH |
|---|---|---|
| Price | $6.25 | $0.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 55.6K | ★ 1.3M |
| Earning Date | 04-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.11 | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $0.51 |
| 52 Week High | $18.45 | $5.33 |
| Indicator | SKIL | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 14.37 |
| Support Level | $3.63 | $0.51 |
| Resistance Level | $8.48 | $3.78 |
| Average True Range (ATR) | 0.64 | 0.08 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 12.04 | 15.49 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.